Cigna biologics denied: how to appeal

Quick answer

If Cigna (Evernorth) denied your biologic and infusion therapy, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: at least 180 days (employer self-funded plans); at least 180 days (insured and Marketplace plans); 65 days from the notice (Medicare Advantage); 65 days from the notice (Part D). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why Cigna (Evernorth) denies biologic and infusion therapy

Cigna serves a large employer-sponsored book and runs Medicare Advantage in select markets. The company's automated 'PXDX' review process for high-volume denials has been the subject of recent litigation and regulatory scrutiny.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

The law that controls this appeal

Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).

At a glance

Cigna (Evernorth) appeals: the rule, the deadline and the next level, by plan type

Which row applies depends on the plan you hold, not on Cigna (Evernorth)'s brand. Your ID card, the Summary Plan Description and the denial letter say which.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Employer self-funded plan (ERISA) Most large employers. The employer pays the claims and hires the carrier to administer them; the Summary Plan Description says self-funded or self-insured.	ERISA § 503 (29 U.S.C. § 1133) and the claims-procedure rule, 29 CFR 2560.503-1. Federal external review under 45 CFR 147.136(d) for non-grandfathered plans.	At least 180 days from the adverse benefit determination (29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days (29 CFR 2560.503-1(i)(2)).	Federal external review by an accredited independent review organization, requested within 4 months of the final internal denial (45 CFR 147.136(d)); then a civil action under ERISA § 502(a). State insurance departments do not regulate self-funded plans; the U.S. Department of Labor does.
Fully insured employer, individual or Marketplace plan The carrier holds the risk and is licensed in your state. Small employers and almost all individual and HealthCare.gov plans.	45 CFR 147.136 (Public Health Service Act § 2719), which applies the 29 CFR 2560.503-1 procedures and adds state external review; state insurance law on top.	At least 180 days from the denial (45 CFR 147.136(b); 29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days. Prior-authorization decisions by Marketplace issuers from 2026: 72 hours expedited, 7 calendar days standard (CMS-0057-F).	External review through your state's process, or the federal process where the state has none, generally within 4 months of the final internal denial (45 CFR 147.136(c), (d)). The state insurance department and its Consumer Assistance Program take complaints.
Medicare Advantage (Part C) A private plan that replaces Original Medicare. The card says Medicare Advantage, HMO, PPO or PFFS.	42 CFR Part 422, Subpart M (§§ 422.560 to 422.634). Coverage decisions must follow Original Medicare rules (42 CFR 422.101).	65 calendar days from the date on the denial notice to request the plan's reconsideration (42 CFR 422.582, as amended effective 1 January 2025).	Expedited: 72 hours. Standard pre-service: 30 days (7 days for Part B drugs). Payment: 60 days (42 CFR 422.590).	If the plan does not fully reverse itself it must send the case to the Independent Review Entity on its own (42 CFR 422.592); then an ALJ hearing when the amount in controversy meets the annual threshold, the Medicare Appeals Council and federal court. State external review does not apply.
Medicare Part D (drug plan or MA-PD) A stand-alone drug plan or the drug benefit inside a Medicare Advantage plan.	42 CFR Part 423, Subpart M; exceptions under 42 CFR 423.578.	65 calendar days from the date on the notice to request a redetermination (42 CFR 423.582, as amended effective 1 January 2025). Formulary, tiering and step-therapy exceptions need the prescriber's supporting statement (§ 423.578).	Redetermination: 7 calendar days standard, 72 hours expedited (42 CFR 423.590). Coverage determinations: 72 hours standard, 24 hours expedited, once the prescriber's statement is received (§§ 423.568, 423.572).	Independent Review Entity reconsideration on your request within 65 days of the redetermination notice (§ 423.600); then ALJ, Council and court.

Employer self-funded plan (ERISA)

What you can demand. The plan must give you the claim file, the internal rule or criterion it relied on, and the identity of the reviewer, free of charge, on request (29 CFR 2560.503-1(h)(2)(iii), (m)(8)).

How to open the appeal. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks.

Fully insured employer, individual or Marketplace plan

What you can demand. The plan must give you the claim file, the criteria it applied and any new evidence or rationale before the final decision, free of charge (45 CFR 147.136(b)(2)(ii)(C); 29 CFR 2560.503-1(h)(2)(iii)).

How to open the appeal. Cite 45 CFR 147.136 and 29 CFR 2560.503-1: request the claim file and the criteria, note the decision clocks, and name the state external-review right.

Medicare Advantage (Part C)

What you can demand. The plan may not apply internal criteria that are more restrictive than Medicare's national and local coverage determinations, and must decide medical necessity on your individual circumstances (42 CFR 422.101(b), (c)). You can ask for the case file and the criteria used.

How to open the appeal. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself.

Medicare Part D (drug plan or MA-PD)

What you can demand. The exception turns on the prescriber's statement that the formulary alternative would be less effective or would harm you (42 CFR 423.578(b)(5)).

How to open the appeal. Cite 42 CFR 423.578 and 423.582 and attach the prescriber's supporting statement written to the exception standard.

Reported denial rates

In the CMS Transparency in Coverage data for plan year 2026 (2024 claims), the 12 Cigna (Evernorth)-family Marketplace issuer filings across 11 states reported in-network claim denial rates from 16.1% to 27.7% (median 20.2%). Issuer-level, self-reported, HealthCare.gov plans only; a denial includes duplicate and administrative denials.

Cigna (Evernorth) denial rate: every state, three years →

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What Cigna (Evernorth) denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
Switch to a second biologic after the first stops working
Dose escalation or interval shortening beyond the label
Infusion at a hospital outpatient department instead of home or a standalone center
Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical Cigna (Evernorth) biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
Disease activity scores or lab markers missing from the record
Diagnosis code does not match the labeled indication
TB or hepatitis B screening not on file
Plan prefers a different biologic or a biosimilar first

The Cigna (Evernorth) appeal process

Appeal levels: Internal level 1 (30 days standard / 72h urgent), then independent external review.

Carrier timing: 180 days from initial denial for level-1 appeal.

Biologics timing: Untreated inflammatory disease supports an expedited appeal: decision within 72 hours. Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D. External review: within 4 months of the final internal denial for ACA-covered plans (45 CFR 147.136).

What we know about Cigna (Evernorth): Cigna's peer-to-peer review window is short, usually a 24-48h scheduling block. We coordinate this directly with the prescribing physician.

Common Cigna (Evernorth) denial patterns for biologic and infusion therapy

Algorithmic ('PXDX') denials. A class of Cigna denials are reviewed only briefly by physicians under an internal automated workflow. Appeals that demand a documented manual clinical review have produced strong reversal rates.
Urgent designation compresses timelines. Cigna honors the urgent flag aggressively when the prescribing doctor signs off. This drops the response window from 30 days to 72 hours.
Out-of-network billing disputes. Cigna's out-of-network reimbursement methodology has shifted multiple times. Rebilling using fair-market reasonable-and-customary data unlocks recoveries on cases coded as 'paid in full.'

How to win your Cigna (Evernorth) biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against Cigna (Evernorth), that strategy rides on this procedural spine:

Procedural-rights anchor. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks. If your Cigna (Evernorth) coverage is a different plan type (Fully insured employer, individual or Marketplace plan, Medicare Advantage, Medicare Part D), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. Cigna (Evernorth) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).
Treating-provider attestation. A letter from the treating physician addressing each criterion in Cigna (Evernorth)'s own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your Cigna (Evernorth) biologic and infusion therapy appeal

The denial letter with the criterion or policy cited
Specialist's notes with diagnosis and disease-activity measures
Prior medication history with dates, doses, and outcomes
TB, hepatitis, and other screening results
The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Cigna (Evernorth) biologic and infusion therapy appeals: frequently asked questions

Cigna (Evernorth) wants me to fail a cheaper drug first. Do I have to?

Not always. Plans must have an exception process, and many states require an override when the required drug was already tried, is contraindicated, or is expected to be ineffective. The prescriber's letter should say which of those applies and why.

Why was my biologic denied when my doctor prescribed it?

Most denials are documentation gaps: a missing severity score, an undocumented prior drug, or a screening lab not on file. The plan's policy tells you exactly which item is missing; request it.

Cigna (Evernorth) moved my infusions out of the hospital. Can I appeal the site of care?

Yes. Site-of-care denials are appealable. The record needs to show why the hospital setting is medically required, for example prior infusion reactions or complex comorbidities.

Is a biosimilar the same drug?

A biosimilar is highly similar to the reference biologic with no clinically meaningful difference, per FDA. Plans may prefer one. If a switch caused loss of response or an adverse reaction, that history is the basis for an exception.

What Apellica does for Cigna (Evernorth) biologic and infusion therapy appeals

We file appeals against Cigna (Evernorth) specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Cigna (Evernorth) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Cigna (Evernorth) biologic and infusion therapy appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

Cigna (Evernorth) denied your biologic and infusion therapy? Here is what to do next